TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits


Despite the success of genome-wide association studies (GWAS) in detecting a large number of loci for complex phenotypes such as rheumatoid arthritis (RA) susceptibility, the lack of information on the causal genes leaves important challenges to interpret GWAS results in the context of the disease biology. Here, we genetically fine-map the RA risk locus at 19p13 to define causal variants, and explore the pleiotropic effects of these same variants in other complex traits. First, we combined Immunochip dense genotyping (n = 23,092 case/control samples), Exomechip genotyping (n = 18,409 case/control samples) and targeted exon-sequencing (n = 2,236 case/controls samples) to demonstrate that three protein-coding variants in TYK2 (tyrosine kinase 2) independently protect against RA: P1104A (rs34536443, OR = 0.66, P = 2.3 x 10(-21)), A928V (rs35018800, OR = 0.53, P = 1.2 x 10(-9)), and I684S (rs12720356, OR = 0.86, P = 4.6 x 10(-7)). Second, we show that the same three TYK2 variants protect against systemic lupus erythematosus (SLE, Pomnibus = 6 x 10(-18)), and provide suggestive evidence that two of the TYK2 variants (P1104A and A928V) may also protect against inflammatory bowel disease (IBD; P(omnibus) = 0.005). Finally, in a phenome-wide association study (PheWAS) assessing >500 phenotypes using electronic medical records (EMR) in >29,000 subjects, we found no convincing evidence for association of P1104A and A928V with complex phenotypes other than autoimmune diseases such as RA, SLE and IBD. Together, our results demonstrate the role of TYK2 in the pathogenesis of RA, SLE and IBD, and provide supporting evidence for TYK2 as a promising drug target for the treatment of autoimmune diseases.

DOI: 10.1371/journal.pone.0122271

Extracted Key Phrases

5 Figures and Tables

Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@inproceedings{Diogo2015TYK2PV, title={TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits}, author={Doroth{\'e}e Diogo and Lisa Bastarache and Katherine P. Liao and Robert R. Graham and Robert S . Fulton and Jeffrey David Greenberg and Stephen Eyre and John Bowes and Jing Cui and Annette Lee and Dimitrios A. Pappas and Joel M. Kremer and Anne Barton and Marieke J. H. Coenen and Barbara Franke and Lambertus A Kiemeney and Xavier Mariette and Corrine Richard-Miceli and Helena Canh{\~a}o and Jo{\~a}o E Fonseca and Niek de Vries and Paul Peter Tak and J. Bart A. Crusius and Michael T. Nurmohamed and Fina A. S. Kurreeman and Ted R Mikuls and Yukinori Okada and Eli Stahl and David E. Larson and Tracie L. Deluca and Michelle D. O'Laughlin and Catrina C. Fronick and Lucinda L. Fulton and Roman Kosoy and Michael T Ransom and Tushar R. Bhangale and Ward A. Ortmann and Andrew Cagan and Vivian S. Gainer and Elizabeth W. Karlson and Isaac S. Kohane and Shawn N. Murphy and Javier Mart{\'i}n and Alexandra Zhernakova and Lars Klareskog and Leonid Padyukov and Jane Worthington and Elaine R. Mardis and Michael F. Seldin and Peter K. Gregersen and Timothy W. Behrens and Soumya Raychaudhuri and Joshua C. Denny and Robert M. Plenge}, booktitle={PloS one}, year={2015} }